The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective
Abstract Background Benchmark data on the population-level economic burden are critical to inform policymakers about liver cancer control. However, comprehensive data in China are currently limited. Methods A prevalence-based approach from a societal perspective was used to quantify the annual econo...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-07-01
|
| Series: | Cost Effectiveness and Resource Allocation |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12962-022-00370-3 |
| _version_ | 1818510017604616192 |
|---|---|
| author | Meng-Di Cao Cheng-Cheng Liu Hong Wang Lin Lei Maomao Cao Yuting Wang He Li Xin-Xin Yan Yan-Jie Li Xin Wang Ji Peng Chunfeng Qu Eleonora Feletto Ju-Fang Shi Wanqing Chen |
| author_facet | Meng-Di Cao Cheng-Cheng Liu Hong Wang Lin Lei Maomao Cao Yuting Wang He Li Xin-Xin Yan Yan-Jie Li Xin Wang Ji Peng Chunfeng Qu Eleonora Feletto Ju-Fang Shi Wanqing Chen |
| author_sort | Meng-Di Cao |
| collection | DOAJ |
| description | Abstract Background Benchmark data on the population-level economic burden are critical to inform policymakers about liver cancer control. However, comprehensive data in China are currently limited. Methods A prevalence-based approach from a societal perspective was used to quantify the annual economic burden of liver cancer in China from 2019 to 2030. Detailed per-case data on medical/non-medical expenditure and work-loss days were extracted from a multicenter survey. The numbers/rates of new/prevalent cases and deaths, survival, and population-related parameters were extracted from the Global Burden of Disease 2019 and the literature. All expenditure data were reported in both 2019 Chinese Yuan (CNY) and United States dollar (US$, for main estimations). Result The overall economic burden of liver cancer was estimated at CNY76.7/US$11.1 billion in China in 2019 (0.047% of the local GDP). The direct expenditure was CNY21.6/US$3.1 billion, including CNY19.7/US$2.9 billion for medical expenditure and CNY1.9/US$0.3 billion for non-medical expenditure. The indirect cost was CNY55.1/US$8.0 billion (71.8% of the overall burden), including CNY3.0/US$0.4 billion due to disability and CNY52.0/US$7.5 billion due to premature death. The total burden would increase to CNY84.2/US$12.2 billion, CNY141.7/US$20.5 billion, and CNY234.3/US$34.0 billion in 2020, 2025, and 2030, accounting for 0.102%, 0.138%, and 0.192% of China's GDP, respectively. However, if China achieves the goals of Healthy China 2030 or the United Nations' Sustainable Development Goals for non-communicable diseases, the burden in 2030 would be < CNY144.4/US$20.9 billion. Conclusions The population-level economic burden of liver cancer in China is currently substantial and will consistently increase in the future. Sustainable efforts in primary and secondary interventions for liver cancer need to be further strengthened. |
| first_indexed | 2024-12-10T22:53:28Z |
| format | Article |
| id | doaj.art-41be5e0610fc4144ac37cbe909cee034 |
| institution | Directory Open Access Journal |
| issn | 1478-7547 |
| language | English |
| last_indexed | 2024-12-10T22:53:28Z |
| publishDate | 2022-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Cost Effectiveness and Resource Allocation |
| spelling | doaj.art-41be5e0610fc4144ac37cbe909cee0342022-12-22T01:30:21ZengBMCCost Effectiveness and Resource Allocation1478-75472022-07-0120111110.1186/s12962-022-00370-3The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspectiveMeng-Di Cao0Cheng-Cheng Liu1Hong Wang2Lin Lei3Maomao Cao4Yuting Wang5He Li6Xin-Xin Yan7Yan-Jie Li8Xin Wang9Ji Peng10Chunfeng Qu11Eleonora Feletto12Ju-Fang Shi13Wanqing Chen14Office of Cancer Screening, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeOffice of Cancer Screening, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeOffice of Cancer Screening, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Cancer Prevention and Control, Shenzhen Center for Chronic Disease ControlOffice of Cancer Screening, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Lab of Molecular Oncology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeOffice of Cancer Screening, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeOffice of Cancer Screening, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeOffice of Cancer Screening, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeOffice of Cancer Screening, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Cancer Prevention and Control, Shenzhen Center for Chronic Disease ControlState Key Lab of Molecular Oncology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeThe Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSWOffice of Cancer Screening, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeOffice of Cancer Screening, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background Benchmark data on the population-level economic burden are critical to inform policymakers about liver cancer control. However, comprehensive data in China are currently limited. Methods A prevalence-based approach from a societal perspective was used to quantify the annual economic burden of liver cancer in China from 2019 to 2030. Detailed per-case data on medical/non-medical expenditure and work-loss days were extracted from a multicenter survey. The numbers/rates of new/prevalent cases and deaths, survival, and population-related parameters were extracted from the Global Burden of Disease 2019 and the literature. All expenditure data were reported in both 2019 Chinese Yuan (CNY) and United States dollar (US$, for main estimations). Result The overall economic burden of liver cancer was estimated at CNY76.7/US$11.1 billion in China in 2019 (0.047% of the local GDP). The direct expenditure was CNY21.6/US$3.1 billion, including CNY19.7/US$2.9 billion for medical expenditure and CNY1.9/US$0.3 billion for non-medical expenditure. The indirect cost was CNY55.1/US$8.0 billion (71.8% of the overall burden), including CNY3.0/US$0.4 billion due to disability and CNY52.0/US$7.5 billion due to premature death. The total burden would increase to CNY84.2/US$12.2 billion, CNY141.7/US$20.5 billion, and CNY234.3/US$34.0 billion in 2020, 2025, and 2030, accounting for 0.102%, 0.138%, and 0.192% of China's GDP, respectively. However, if China achieves the goals of Healthy China 2030 or the United Nations' Sustainable Development Goals for non-communicable diseases, the burden in 2030 would be < CNY144.4/US$20.9 billion. Conclusions The population-level economic burden of liver cancer in China is currently substantial and will consistently increase in the future. Sustainable efforts in primary and secondary interventions for liver cancer need to be further strengthened.https://doi.org/10.1186/s12962-022-00370-3Liver cancerCost of illnessChinaPopulation-levelPrevalence |
| spellingShingle | Meng-Di Cao Cheng-Cheng Liu Hong Wang Lin Lei Maomao Cao Yuting Wang He Li Xin-Xin Yan Yan-Jie Li Xin Wang Ji Peng Chunfeng Qu Eleonora Feletto Ju-Fang Shi Wanqing Chen The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective Cost Effectiveness and Resource Allocation Liver cancer Cost of illness China Population-level Prevalence |
| title | The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective |
| title_full | The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective |
| title_fullStr | The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective |
| title_full_unstemmed | The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective |
| title_short | The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective |
| title_sort | population level economic burden of liver cancer in china 2019 2030 prevalence based estimations from a societal perspective |
| topic | Liver cancer Cost of illness China Population-level Prevalence |
| url | https://doi.org/10.1186/s12962-022-00370-3 |
| work_keys_str_mv | AT mengdicao thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT chengchengliu thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT hongwang thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT linlei thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT maomaocao thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT yutingwang thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT heli thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT xinxinyan thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT yanjieli thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT xinwang thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT jipeng thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT chunfengqu thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT eleonorafeletto thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT jufangshi thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT wanqingchen thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT mengdicao populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT chengchengliu populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT hongwang populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT linlei populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT maomaocao populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT yutingwang populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT heli populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT xinxinyan populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT yanjieli populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT xinwang populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT jipeng populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT chunfengqu populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT eleonorafeletto populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT jufangshi populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT wanqingchen populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective |